D.A. Davidson & Co. Outlook Therapeutics, Inc. Transaction History

D.A. Davidson & Co.

  • $12 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023
BUY
$0.2 - $1.78 $5,600 - $49,840
28,000 New
28,000 $6,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $536M
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track D.A. Davidson & Co. Portfolio

Follow D.A. Davidson & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email